CONCLUSION
Efficacy and safety results observed with asciminib in this Japanese subgroup are comparable to those previously reported for the overall study population in the ASCEMBL study. The findings support asciminib as a new therapeutic option for Japanese patients with CML‐CP after prior treatment with TKIs.